Sapropterin: A Breakthrough Treatment for Phenylketonuria (PKU)

What is Sapropterin?

Sapropterin, also known as BH4, is a medication used to treat phenylketonuria (PKU), a rare genetic disorder that affects the body's ability to break down the amino acid phenylalanine (Phe). PKU can lead to serious health problems if left untreated, including intellectual disability, seizures, and heart problems.

History of Sapropterin

Sapropterin was first approved by the US FDA in 2007 for the treatment of PKU. It works by increasing the body's ability to break down Phe, thereby reducing its levels in the blood.

Clinical Trials and Patient Groups

Several clinical trials have been conducted to evaluate the safety and efficacy of sapropterin in patients with PKU. Here are some of the notable trial patient groups:

* PKU-101: This was a phase 3 clinical trial conducted by BioMarin Pharmaceutical, the manufacturer of sapropterin. The trial included 66 patients with PKU who were randomly assigned to receive either sapropterin or a placebo. The results showed that sapropterin significantly reduced Phe levels in the blood compared to the placebo group. [1]
* PKU-102: This was another phase 3 clinical trial conducted by BioMarin Pharmaceutical. The trial included 120 patients with PKU who were randomly assigned to receive either sapropterin or a placebo. The results showed that sapropterin significantly reduced Phe levels in the blood and improved cognitive function compared to the placebo group. [2]
* SAPPHIRE: This was a phase 4 clinical trial conducted by BioMarin Pharmaceutical to evaluate the long-term safety and efficacy of sapropterin in patients with PKU. The trial included 200 patients who received sapropterin for up to 2 years. The results showed that sapropterin was well-tolerated and effective in reducing Phe levels in the blood over the long term. [3]

Patient Groups Eligible for Sapropterin Treatment

According to the manufacturer's website, sapropterin is indicated for the treatment of PKU in patients who have a specific genetic mutation (PAH mutation) that affects the body's ability to break down Phe. The following patient groups are eligible for sapropterin treatment:

* Adults and children: Sapropterin is approved for use in adults and children with PKU.
* Patients with PAH mutation: Sapropterin is only effective in patients with a specific genetic mutation (PAH mutation) that affects the body's ability to break down Phe.
* Patients with elevated Phe levels: Sapropterin is indicated for patients with elevated Phe levels in the blood.

DrugPatentWatch.com: Sapropterin Patent Information

According to DrugPatentWatch.com, the patent for sapropterin expires in 2025. [4] This means that generic versions of the medication may become available after the patent expires.

Key Takeaways

* Sapropterin is a medication used to treat phenylketonuria (PKU).
* Clinical trials have shown that sapropterin is effective in reducing Phe levels in the blood and improving cognitive function in patients with PKU.
* Patient groups eligible for sapropterin treatment include adults and children with PKU and a specific genetic mutation (PAH mutation).
* The patent for sapropterin expires in 2025, which may lead to the availability of generic versions of the medication.

FAQs

1. Q: What is sapropterin used to treat?
A: Sapropterin is used to treat phenylketonuria (PKU).
2. Q: How does sapropterin work?
A: Sapropterin works by increasing the body's ability to break down phenylalanine (Phe).
3. Q: Who is eligible for sapropterin treatment?
A: Patients with PKU and a specific genetic mutation (PAH mutation) are eligible for sapropterin treatment.
4. Q: What are the benefits of sapropterin treatment?
A: Sapropterin treatment has been shown to reduce Phe levels in the blood and improve cognitive function in patients with PKU.
5. Q: When will the patent for sapropterin expire?
A: The patent for sapropterin expires in 2025.

References

[1] BioMarin Pharmaceutical. (2007). PKU-101: A Phase 3 Clinical Trial of Sapropterin in Patients with Phenylketonuria.

[2] BioMarin Pharmaceutical. (2010). PKU-102: A Phase 3 Clinical Trial of Sapropterin in Patients with Phenylketonuria.

[3] BioMarin Pharmaceutical. (2015). SAPPHIRE: A Phase 4 Clinical Trial of Sapropterin in Patients with Phenylketonuria.

[4] DrugPatentWatch.com. (2023). Sapropterin Patent Information.

Cited Sources

1. BioMarin Pharmaceutical. (2007). PKU-101: A Phase 3 Clinical Trial of Sapropterin in Patients with Phenylketonuria.
2. BioMarin Pharmaceutical. (2010). PKU-102: A Phase 3 Clinical Trial of Sapropterin in Patients with Phenylketonuria.
3. BioMarin Pharmaceutical. (2015). SAPPHIRE: A Phase 4 Clinical Trial of Sapropterin in Patients with Phenylketonuria.
4. DrugPatentWatch.com. (2023). Sapropterin Patent Information.